PLUR (Pluri Inc) Earnings growth in current year

PLUR (Pluri Inc.) - company brandmark

Pluri Inc. develops cellular therapies to combat metabolic pathologies. The annual growth of net income per share as a percentage reflects the company's dynamics, with the latest value recorded as 0.00. The business relies on robust cold chain logistics, overcoming fierce competition from pharma behemoths. Meanwhile, the operational footprint remains minimal due to strict compliance with bio-waste disposal standards.

PLUR: pluri-biotech.com Earnings per share growth in current year 04/28/2023 - 11/14/2026

Financial and market metric breakdowns for pluri-biotech.com (PLUR)

- share price and expert price forecast:
Price Pluri|PLUR - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization PLUR|PLUR - Enterprise Value
- book capitalization data:
Net Assets per Single Share Pluri|PLUR - Company Book Value|Market-to-Book Ratio pluri-biotech.com|PLUR - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Equity Pluri Inc.|PLUR - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Pluri|PLUR - Company Debts|Debts to Net Assets PLUR|PLUR - Company Long-Term Debt|Company Current Liabilities Pluri|Critical Liquidity Ratio pluri-biotech.com
- earnings and valuation multiples information:
PLUR - Company Net Income|Expected Profit Pluri Inc.|PLUR - Price to Earnings Ratio|Forward P/E Multiple Pluri|PLUR - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation PLUR|PLUR - Operating profit EBITDA|Net earnings per share for the last four quarters Pluri|PLUR - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months pluri-biotech.com|PLUR - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Pluri Inc.
- revenue and sales proceeds data:
PLUR - Company Revenue|Company Revenue Forecast Pluri|PLUR - P/S Multiple|Forward Price-to-Revenue Multiple PLUR
Basic company analysis:PLUR - Pluri Inc
Finished products of Pluri Inc

Business operational efficiency is determined by the ability to generate net income per share. This metric measures the annual EPS trend, reflecting margin growth or the effect of share count reduction. For Pluri Inc. (PLUR), this trend confirms the commercialization of 3D bioreactors and the scaling of cell technologies. By analyzing the relative EPS growth over 12 months, an investor assesses the actual expansion of the business.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Pharma) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics Corp|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (akerotx.com)|Earnings per share growth in current year Metsera MTSR|MoonLake Immunotherapeutics AG (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio|Agios (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year Structure Pharma (GPCR)|Net earnings per share growth this year MiMedx Corp MDXG|Earnings per share growth in current year Rezolute, Inc. RZLT|LXRX (lexpharma.com) - Earnings per share trend in current year|MBX - Earnings per share growth in current year|ALT: Earnings per share growth in current year|AARD (Aardvark Therapeutics Corp) - Net earnings per share growth this year|Sagimet Biosciences Inc (SGMT) - Earnings growth in current year|Earnings per share growth in current year BioAge Labs, Inc.|BMEA: Earnings per share increase in current year|Earnings growth in current year QNCX|Expected net earnings per share growth this year Fractyl Health Inc.|vTv Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year ATPC|Synlogic Corp - Earnings growth in current year|Expected net earnings per share growth this year lipocine.com LPCN|matinasbiopharma.com (MTNB) - Earnings per share growth in current year|Earnings per share growth this year SPRB|GLTO (Galecto Corp) - Earnings growth in current year|Net earnings per share growth this year Carmell Therapeutics (CTCX)|Net earnings per share growth this year LUMO (Lumos Pharma, Inc.)|Expected net earnings per share growth this year organovo.com|Earnings per share growth in current year Radius Recycling RDUS